Haemonetics Corp. (HAE) Tops Q3 EPS by 3c; Reaffirms Outlook
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $77.29 -0.43%
EPS Growth %: -0.9%
Financial Fact:
Research, development and engineering: 8.34M
Today's EPS Names:
CGEH, NAKA, APOG, More
EPS Growth %: -0.9%
Financial Fact:
Research, development and engineering: 8.34M
Today's EPS Names:
CGEH, NAKA, APOG, More
Join SI Premium – FREE
Haemonetics Corp. (NYSE: HAE) reported Q3 EPS of $0.50, $0.03 better than the analyst estimate of $0.47. Revenue for the quarter came in at $247.4 million versus the consensus estimate of $251.93 million.
Reaffirmed FY13 and FY14 guidance.
For earnings history and earnings-related data on Haemonetics Corp. (HAE) click here.
Reaffirmed FY13 and FY14 guidance.
For earnings history and earnings-related data on Haemonetics Corp. (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
- Argus starts SpaceX at Hold, sees record IPO as a multi-year re-rating challenge
- UBS Downgrades Grand Korea Leisure (114090:KS) to Neutral
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
